Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma

[1]  M. Ghielmini,et al.  Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Ansell,et al.  Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. , 2009, Cancer research.

[3]  M. Farrar,et al.  IL-2, -7, and -15, but Not Thymic Stromal Lymphopoeitin, Redundantly Govern CD4+Foxp3+ Regulatory T Cell Development1 , 2008, The Journal of Immunology.

[4]  S. Ansell,et al.  CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. , 2007, Blood.

[5]  Michael L. Wang,et al.  Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B‐cell non‐Hodgkin lymphoma , 2007, British journal of haematology.

[6]  S. Ansell,et al.  Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. , 2006, Cancer research.

[7]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[8]  S. Ansell,et al.  Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. , 2005, Blood.

[9]  J. Hainsworth,et al.  Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Habermann,et al.  Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Michael L. Wang,et al.  Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Abbas,et al.  CD4+CD25+ Cells Controlling a Pathogenic CD4 Response Inhibit Cytokine Differentiation, CXCR-3 Expression, and Tissue Invasion1 , 2004, The Journal of Immunology.

[13]  H. Lyerly,et al.  Immunoregulatory T cells in cancer immunotherapy , 2002, Expert opinion on biological therapy.

[14]  J. Hainsworth,et al.  Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[16]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[17]  C. June,et al.  Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.

[18]  D. Sargent,et al.  A three-outcome design for phase II clinical trials. , 2001, Controlled clinical trials.

[19]  T. Habermann,et al.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[21]  J. Ledbetter,et al.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer Immunology, Immunotherapy.

[22]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Glennie,et al.  Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. , 1998, Cancer research.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .